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Abnormal N-terminal fragment of brain natriuretic
peptide in patients with light chain amyloidosis
without cardiac involvement at presentation is 
a risk factor for development of cardiac 
amyloidosis
Primary light chain (AL) amyloidosis, the commonest
type of amyloidosis, presents with cardiac involvement
in 50% of patients.  Cardiac amyloidosis causes a restric-
tive cardiomyopathy and is the major determinant of
treatment related toxicity and death.1 Echocardiography
remains the gold standard for non-invasive patient
assessment2 although other techniques like cardiac MRI
(CMR) scanning3 appear to hold promise.  N-terminal
fragment of brain natriuretic peptide (NT-proBNP) is
abnormal in cardiac amyloidosis4 and high levels are
associated with poor prognosis.4,5 Early changes in NT-
proBNP concentration occur after chemotherapy but the
basis and significance remains unclear.6 The significance
of elevated NT-proBNP in the absence of cardiac involve-
ment by the international consensus criteria (ICC)7 has
not been well studied. 
We report significance of NT-proBNP in 102 patients
with AL amyloidosis who did not have cardiac involve-
ment by ICC amongst a stringently selected group of
169 patients with preserved renal function (creatinine
clearance or eGFR >50 mL/min, <10% change in eGFR
following treatment) who underwent assessment within
protocols at the UK National Amyloidosis Centre (NAC)
between 1999-2006, had a confirmed diagnosis of AL
amyloidosis and had archived serum samples for retro-
spective analyses.  NT-proBNP was measured using a
Roche Elecsys 2010 analyzer and Roche Diagnostics
assay kit.  NT-proBNP cut off of 39 pMol/L (332 ng/L)
was used based on previous reports.5 This study was per-
formed with informed consent from each patient in
accordance with the Declaration of Helsinki, and
received institutional review board approval.
The median age was 56 years (range 32-84) and a
median number of 2 organs were involved: liver n=26
(16%), renal n=123 (73%), cardiac n=67 (40%). Median
ECOG performance status was 2 (range 0-3). There was
no significant difference in baseline characteristics
between those with or without cardiac involvement.
The median NT-proBNP for the whole cohort was 50
pMol/L (range 1-2525 pMol/L).  NT-proBNP had a high
degree of sensitivity for cardiac involvement (area under
ROC curve 0.88, 95%CI 0.82-0.93). NT-ProBNP of 39
pMol/L had 89% sensitivity and 65% specificity for car-
diac involvement (ICC7 as gold standard) and had a sig-
nificant impact on survival (P=0.003; data not shown).
One hundred and two of 169 (60%) patients had no
evidence of cardiac involvement by ICC7 and had medi-
an left ventricular wall thickness of 9 mm (7-11 mm).
Forty of 102 (39%) had NT-proBNP of greater than 39
pMol/L with no significant difference in the baseline
characteristics if NT-proBNP was equal to or less than or
greater than 39 pMol/L, including response to
chemotherapy (5 in each group did not respond
(P=0.46)). NT-proBNP cut off 39 pMol/L remained prog-
nostically significant in this subgroup and even lower
NT-proBNP thresholds had prognostic significance;
patients with NT-proBNP less than 15 pMol/L had better
outcomes (HR 0.12; 95%CI 0.013-0.79; P=0.029) versus
those with higher values with Kaplan-Meier estimated
5-year survival 98% versus 88%, respectively (Figure 1A;
log rank P=0.007). On a median follow up of 60 months,
19 of 40 (47%) patients with NT-proBNP greater than 39
pMol/L at diagnosis had developed evidence of cardiac
involvement by ICC compared to only 6 of 62 (10%) of
those with NT-proBNP 39 pMol/L or below (relative risk
4.89; P<0.001) (Figure 1B).
After chemotherapy treatment using previously
described regimes,8-11 we confirmed earlier reports6 of a
significant decrease in NT-proBNP (median 444 to 144
pMol/L; P=0.021) among complete clonal responders, no
significant change in partial responders, and a significant
increase (from a median 53 pMol/L to 136 pMol/L;
P<0.0001) in non-responders with no impact of NT-
proBNP changes on survival in this stringently selected
cohort. In summary, patients with AL amyloidosis who
have modestly elevated NT-proBNP (>39 pMol/L) at
presentation but no evidence of cardiac amyloidosis by
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Figure 1. (A) Kaplan-Meier estimated overall survival for patients
who did not have cardiac involvement by international consensus
criteria (ICC) stratified by presenting NT-proBNP using a low
threshold of 15 pMol/L. Patients with NT-proBNP over 15 pMol/L
had worse outcomes even in the absence of cardiac involvement
by ICC. (B) Kaplan-Meier estimated cumulative risk for develop-
ment of cardiac amyloidosis by ICC in patients presenting with no
evidence of cardiac amyloidosis but having presenting NT-proBNP
over 39 pMol/L.
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consensus criteria have a significantly higher risk (47%
vs. 10% respectively; P<0.001) of developing cardiac
amyloidosis than those with lower values (<39 pMol/L).
Even subtle elevations of NT-proBNP (>15 pMol/L) have
prognostic significance in patients without cardiac
involvement by ICC, although the retrospective nature
of this study limits identification of true causes of death.
It appears likely that subtle elevation of NT-proBNP may
predict existing cardiac amyloidosis which cannot be
identified at echocardiography highlighting both the lim-
itation of echocardiography and current consensus crite-
ria for detecting early cardiac involvement. There is an
urgent need to validate other tools, such as CMR and use
of cardiac biomarkers, for early diagnosis of cardiac amy-
loidosis. These important observations need to be
extended and confirmed in larger populations. Studies
targeting this patient group with highly effective first-
line treatments like bortezomib are needed to prove that
cardiac amyloid progression can be prevented.
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